Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2230-2236

  Kim, Sangmin ^a   Jeon, Myeongjin ^a,b   Lee, Jeongmin ^a   Han, Jeonghun ^a   Oh, Soo Jin ^a,b   Jung, Taewoo ^a,b   Nam, Seok Jin ^a   Kil, Won Ho ^a   Lee, Jeong Eon ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Epidermal growth factor receptor; Fibronectin; Silibinin; STAT3; Triple negative breast cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; SILIBININ; STAT3 PROTEIN; UO 126; ANTINEOPLASTIC AGENT; ANTIOXIDANT; QUINAZOLINE DERIVATIVE; SILYMARIN; TYRPHOSTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; FEMALE; FIBRONECTINS; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; QUINAZOLINES; SIGNAL TRANSDUCTION; SILYMARIN; TRIPLE NEGATIVE BREAST NEOPLASMS; TYRPHOSTINS;

EID: 84907291514     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3450     Document Type: Article

References (37)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
2. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
3. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
4. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987.
5. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
6. Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP and Carlin CR: Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem 288: 17954-17967, 2013.
7. Wendt MK, Smith JA and Schiemann WP: Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29: 6485-6498, 2010.
8. Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci 115: 3861-3863, 2002.
9. Ritzenthaler JD, Han S and Roman J: Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst 4: 1160-1169, 2008.
10. Fernandez-Garcia B, Eiro N, Marin L, Gonzalez-Reyes S, Gonzalez LO, Lamelas ML and Vizoso FJ: Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology: 512-522, 2013.
11. Bae YK, Kim A, Kim MK, Choi JE, Kang SH and Lee SJ: Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44: 2028-2037, 2013.
12. Rintoul RC and Sethi T: Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci 102: 417-424, 2002.
13. Sharma G, Singh RP, Chan DC and Agarwal R: Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res 23: 2649-2655, 2003.
14. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE: Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine 16: 573-580, 2009.
15. Kim S, Kim SH, Hur SM, Lee SK, Kim WW, Kim JS, Kim JH, Choe JH, Nam SJ, Lee JE and Yang JH: Silibinin prevents TPA-induced MMP-9 expression by downregulation of COX-2 in human breast cancer cells. J Ethnopharmacol 126: 252-257, 2009.
16. Kim S, Han J, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE: Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells. Anticancer Res 31: 3767-3773, 2011.
17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.
18. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M and Yarden Y: Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci USA 110: 1815-1820, 2013.
19. Choi J, Jung WH and Koo JS: Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol 27: 1481-1493, 2012.
20. Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A and Guler G: EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet 203: 222-229, 2010.
21. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
22. Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L and Frattini M: Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol and Histopathol 27: 785-792, 2012.
23. Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X and Qin T: EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29: 401-405, 2012.
24. Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, Price JT and Thompson EW: Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 83: 435-448, 2003.
25. Sun X, Fa P, Cui Z, Xia Y, Sun L, Li Z, Tang A, Gui Y and Cai Z: The EDA-containing cellular fibronectin induces epithelialmesenchymal transition in lung cancer cells through integrin α9β1-mediated activation of PI3-K/AKT and Erk1/2. Carcinogenesis 35: 184-191, 2014.
26. Sudo T, Iwaya T, Nishida N, Sawada G, Takahashi Y, Ishibashi M, Shibata K, Fujita H, Shirouzu K, Mori M and Mimori K: Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma. Ann Surg Oncol 20: S324-S335, 2013.
27. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, Kim JS, Kim JH, Choe JH, Nam SJ, Lee JE and Yang JH: EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal 21: 892-898, 2009.
28. Kim S, Han J, Lee SK, Koo M, Cho DH, Bae SY, Choi MY, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE: Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Lett 314: 147-154, 2012.
29. Hayashida T, Poncelet AC, Hubchak SC and Schnaper HW: TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56: 1710-1720, 1999.
30. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S and Iwasaka T: Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int 62: 799-808, 2002.
31. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA and Berns EM: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14: 5555-5564, 2008.
32. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D and Park C: Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67: 659-664, 2007.
33. Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, Giovinazzo G, Santino A, Storelli C and Maffia M: Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett 310: 1-8, 2011.
34. Grande M, Franzen A, Karlsson JO, Ericson LE, Heldin NE and Nilsson M: Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci 115: 4227-4236, 2002.
35. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via upregulation of TWIST gene expression. Cancer Res 67: 9066-9076, 2007.
36. Kasai H, Allen JT, Mason RM, Kamimura T and Zhang Z: TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 6: 56, 2005.
37. Cheung CW, Gibbons N, Johnson DW and Nicol DL: Silibinin-A promising new treatment for cancer. Anticancer Agents Med Chem 10: 186-195, 2010.